Ascletis announces that oral viral polymerase inhibitor ASC10 and derivatives have received notice of grant of U.S. patents

Ascletis Pharmaceuticals Limited (HKEx code: 1672, "Ascletis") announced on December 19 that patent for the patent for oral viral polymerase inhibitor ASC10 and derivatives for the treatment of multiple viral infections including novel coronavirus, monkeypox virus and human respiratory syncytial virus (RSV) and its use patent application have been notified by the United States Patent and Trademark Office (USPTO
).
The USPTO patent grant date is January 3, 2023, and the patent is entitled "Nucleoside derivatives and their uses" (U.
S.
Patent Publication No.
11,541,071).

ASC10 is an oral dual prodrug with a new, differentiated chemical structure
compared to the monoprodrug molnupiravir.
After oral administration, both ASC10 and monoravir are rapidly and completely converted in the body to the same active drug ASC10-A, also known as β-D-N4-hydroxycytidine (NHC) or EIDD-1931
.
The ASC10 was developed
entirely in-house by Ascletis.

With this patent grant, Ascletis became the first Chinese biotechnology company
to be granted a patent by the U.
S.
Patent and Trademark Office for the independent development of oral viral polymerase inhibitors and derivatives.
The grant will extend the commercial protection of ASC10 and derivatives and their uses until 2042
.

"The patented compound patents for oral viral polymerase inhibitors ASC10 and derivatives and their use patents have been granted in the United States, further strengthening our patent footprint
in the field of viral diseases.
ASC10 has broad-spectrum antiviral activity and is expected to unlock more potential
in addressing multiple viral challenges.
I look forward to accelerating clinical research to benefit more patients
.
" Dr.
Jinzi Wu, Founder, Chairman of the Board and Chief Executive Officer of Ascletis, said
.